PortfoliosLab logoPortfoliosLab logo
CRDF vs. ATXS
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CRDF vs. ATXS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cardiff Oncology, Inc. (CRDF) and Astria Therapeutics, Inc. (ATXS). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CRDF vs. ATXS - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRDF
Cardiff Oncology, Inc.
-42.70%-35.25%193.24%5.71%-76.71%-66.59%1,350.81%-60.67%-85.76%-85.36%
ATXS
Astria Therapeutics, Inc.
-3.90%46.42%16.41%-48.42%176.25%-58.02%-63.79%35.24%-70.67%-58.73%

Fundamentals

Market Cap

CRDF:

$107.61M

ATXS:

$729.71M

EPS

CRDF:

-$0.69

ATXS:

-$2.14

PS Ratio

CRDF:

234.13

ATXS:

1.03K

PB Ratio

CRDF:

2.37

ATXS:

5.29

Total Revenue (TTM)

CRDF:

$459.00K

ATXS:

$706.00K

Gross Profit (TTM)

CRDF:

-$11.12M

ATXS:

$706.00K

EBITDA (TTM)

CRDF:

-$47.20M

ATXS:

-$134.05M

Returns By Period


CRDF

1D
-0.62%
1M
-17.01%
YTD
-42.70%
6M
-22.60%
1Y
-47.39%
3Y*
-0.81%
5Y*
-30.09%
10Y*
-41.56%

ATXS

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Cardiff Oncology, Inc.

Astria Therapeutics, Inc.

Often compared with CRDF:
CRDF vs. VSTM
Often compared with ATXS:
ATXS vs. VOO

Return for Risk

CRDF vs. ATXS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRDF
CRDF Risk / Return Rank: 1818
Overall Rank
CRDF Sharpe Ratio Rank: 1616
Sharpe Ratio Rank
CRDF Sortino Ratio Rank: 2020
Sortino Ratio Rank
CRDF Omega Ratio Rank: 1919
Omega Ratio Rank
CRDF Calmar Ratio Rank: 1515
Calmar Ratio Rank
CRDF Martin Ratio Rank: 1919
Martin Ratio Rank

ATXS
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRDF vs. ATXS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cardiff Oncology, Inc. (CRDF) and Astria Therapeutics, Inc. (ATXS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CRDFATXSDifference

Sharpe ratio

Return per unit of total volatility

-0.57

Sortino ratio

Return per unit of downside risk

-0.43

Omega ratio

Gain probability vs. loss probability

0.94

Calmar ratio

Return relative to maximum drawdown

-0.73

Martin ratio

Return relative to average drawdown

-1.14

CRDF vs. ATXS - Sharpe Ratio Comparison


Loading graphics...

Sharpe Ratios by Period


CRDFATXSDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.57

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.30

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.39

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.23

Correlation

The correlation between CRDF and ATXS is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

CRDF vs. ATXS - Dividend Comparison

Neither CRDF nor ATXS has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CRDF vs. ATXS - Drawdown Comparison


Loading graphics...

Drawdown Indicators


CRDFATXSDifference

Max Drawdown

Largest peak-to-trough decline

-99.96%

Max Drawdown (1Y)

Largest decline over 1 year

-66.74%

Max Drawdown (5Y)

Largest decline over 5 years

-90.44%

Max Drawdown (10Y)

Largest decline over 10 years

-99.84%

Current Drawdown

Current decline from peak

-99.92%

Average Drawdown

Average peak-to-trough decline

-86.06%

Ulcer Index

Depth and duration of drawdowns from previous peaks

42.87%

Volatility

CRDF vs. ATXS - Volatility Comparison


Loading graphics...

Volatility by Period


CRDFATXSDifference

Volatility (1M)

Calculated over the trailing 1-month period

16.19%

Volatility (6M)

Calculated over the trailing 6-month period

63.44%

Volatility (1Y)

Calculated over the trailing 1-year period

83.75%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

99.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

105.87%

Financials

CRDF vs. ATXS - Financials Comparison

This section allows you to compare key financial metrics between Cardiff Oncology, Inc. and Astria Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00K400.00K600.00K800.00KAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
109.00K
706.00K
(CRDF) Total Revenue
(ATXS) Total Revenue
Values in USD except per share items